A phase 2 randomized, controlled trial of the α7 agonist ABT‐126 in mild‐to‐moderate Alzheimer's dementia
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Introduction: The safety and efficacy of the novel α7 nicotinic acetylcholine receptor agonist ABT‐126 were investigated in subjects with mild‐to‐moderate Alzheimer's dementia (AD). Methods: Subjects not currently receiving acetylcholinesterase inhibitors were randomized to ABT‐126 (5 or 25 mg once daily), donepezil 10 mg once daily, or placebo for 12 weeks. The primary efficacy end point was the change from baseline to final evaluation in the 11‐item Alzheimer's Disease Assessment Scale‐cognitive subscale (ADAS‐Cog) total score. Results: A total of 274 subjects were randomized. Although the study did not meet its primary end point, trends toward improvement were seen with ABT‐126 25 mg (least squares mean [standard error] difference from placebo −1.19 [0.90]; one‐sided P = .095) and donepezil (−1.43 [0.90]; one‐sided P = .057) on the 11‐item ADAS‐Cog total score change from baseline to the final evaluation. ABT‐126 5 mg was numerically similar to placebo. An exposure‐response analysis indicated a statistically significant relationship between ABT‐126 exposure and the change from baseline in ADAS‐Cog, with no evidence of a plateau. No clinically meaningful differences in safety were observed among treatment groups. Discussion: Although the ABT‐126 25 mg dose did not demonstrate statistically significant improvement, results of the exposure‐response analysis suggest that higher doses may produce better efficacy, and the safety profile of ABT‐126 in this study supports additional studies with higher doses in subjects with mild‐to‐moderate AD. Clinical trial register number: NCT00948909 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Physician Withdrawal Checklist (PWC-20)
Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817efbac · Cited by 59 · cited 2×
“Exploratory analyses indicated a statistically significantly higher LS mean PWC-20 score for the ABT-126 25 mg group (3.32, SE 5 0.38) compared with placebo (1.64, SE 5 0.38, P 5 .002).”
MethodInfluential
Cited by
d’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Burns, L. H., Pei, Z., & Wang, H. (2023) · Drug Development Research · doi:10.1002/ddr.22085 · Cited by 35
Stoiljkovic, M., Leventhal, L., Chen, A., Chen, T., Driscoll, R., Flood, D., Hodgdon, H., Hurst, R., Nagy, D., Piser, T., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.006 · Cited by 29
Metadata
- Authors
- Gault, L. M., Ritchie, C. W., Robieson, W. Z., Pritchett, Y., Othman, A. A., & Lenz, R. A.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2015-06
- Volume
- 1
- Issue
- 1
- Pages
- 81-90
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2138338009
- Cited by
- 41
- References
- 5
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.